Answering the “Doctor, can CAR-T therapy cause cancer?” question in clinic-Reference-Cited by-同舟云学术

Answering the “Doctor, can CAR-T therapy cause cancer?” question in clinic

Published:2024-02-15 Issue:4 Volume:8 Page:895-898
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Banerjee Rahul¹²^ORCID,Poh Christina¹²,Hirayama Alexandre V.¹²^ORCID,Gauthier Jordan¹²^ORCID,Cassaday Ryan D.¹²,Shadman Mazyar¹²,Cowan Andrew J.¹²,Till Brian G.¹²,Green Damian J.¹²^ORCID,Kiem Hans-Peter¹²^ORCID,Gopal Ajay K.¹²^ORCID,Maloney David G.¹²

Affiliation:

1. 1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA

2. 2Department of Medicine, University of Washington, Seattle, WA

Publisher

American Society of Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/8/4/895/2215181/blooda_adv-2023-012336-main.pdf

Reference39 articles.

1. FDA opens review of CAR-T safety after identifying 19 cases of post-treatment blood cancer;DeFeudis;Endpoints News,28 2023

2. FDA investigates ‘serious risk’ of secondary cancer following CAR-T treatment;Liu;Fierce Pharma,28 2023

3. CAR+ T-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma;Harrison;Blood,2023

4. Kolata G . Innovative cancer treatment may sometimes cause cancer, FDA says. New York Times. 28 November 2023. Accessed 23 January 2024. https://www.nytimes.com/2023/11/28/health/fda-car-t-blood-cancer.html.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?;International Journal of Molecular Sciences;2024-09-01

2. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee;The Lancet Oncology;2024-08

3. Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase;eClinicalMedicine;2024-07

4. CAR T-cell Resistance to Oncogenic Transformation;Blood Cancer Discovery;2024-06-21

5. Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma;Frontiers in Oncology;2024-06-11